Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients

Annals of Intensive Care

Table 3 Relationship between biomarkers variations between Day 0 and Day 3–4 and the outcome

	Survivors	Non-survivors	p-value for univariate comparison	Adjusted*** HR [95% CI]	p-value
Lymphocyte ratio*	16.4 [− 4.5, 53.3]	− 23.6 [− 54.5, 20.6]	0.02	0.9 [0.8–1.0]	0.05
Delta Lymphocyte**	− 160.0 [− 395.0, 65.0]	0 [− 40.0, 460.0]	0.01	1.2 [1.1–1.4]	0.01
CRP ratio	− 45.7 [− 62.6, 14.9]	13.9 [− 20.3, 32.1]	0.04	1.0 [0.9–1.1]	0.44
Delta CRP	39.5 [− 12.0, 114.6]	− 34.0 [− 68.7, 65.7]	0.05	0.6 [0.4–0.9]	0.01
Fibrinogen ratio	− 0.02 [− 0.88, 0.29]	0.16 [− 0.01, 0.35]	0.155	1.41 [0.77–2.57]	0,25
Delta Fibrinogen	− 0.11 [− 1.18, 0.54]	0.36 [− 0.03, 1.00]	0.05	1.40 [0.96–2.05]	0.08
IL-6 ratio	− 14.5 [− 29.3, 0.4]	− 6.6 [− 21.0, 0.2]	0.55	1.2 [0.8–1.6]	0.37
Delta IL-6	− 0.7 [− 1.6, 0]	− 0.4 [− 1.0, 0]	0.66	0.9 [0.5–1.8]	0.83

Results are given as Median [IQR] and Hazard Ratio (HR) [95%CI], *Ratio: percentage of change from Day 0 value; ** delta between Day0 and Day 3–4 values; ***Adjusted on SOFA at ICU admission and time from symptom onset to first dosage